Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Study sponsor: TG Therapeutics, Inc. · TGTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12-12Estimated
Enrollment · participants60Estimated
Source updated2026-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.